Were you and your team focusing on manufacturing efficiency, solid tumor durability, accessibility, safety, cost-efficiency, product release times, autoimmune indications, armoring, potency assays, resistance or investment for your cell therapy pipelines this year?

The 9^th CAR-TCR Summit agenda had been created in collaboration with the cell therapy industry, for the cell therapy industry to address common challenges like these and many more. If you wanted to discuss these topics with like-minded industry experts and leading academics, then this was the only meeting you needed to attend in 2024.

Attendees gained in-depth insights that were specific to their functional role, whether their focus was on Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, Analytical Development or Supply Chain & Clinical Operations.

Plus, attendees enjoyed improved networking opportunities, new bonus days, reduced rates, drinks receptions, scientific poster sessions and more.

With recent expanded approvals for BMS’s Breyanzi and Johnson & Johnson’s Carvykti and further approvals set for this year, attendees joined this industry at a pivotal time to celebrate the successes and overcome challenges together to deliver more curative treatments to the ever-growing population of patients in need.

View the Full 2024 Agenda to see the speaker faculty, what was new for 2024, full session details, who attendees met and much more!